Loading clinical trials...
Loading clinical trials...
An Open-label Study of the Effect of the Addition of MabThera to Standard Chemotherapy on Clinical Response in Patients With Previously Untreated Mantle Cell Lymphoma
Conditions
Interventions
rituximab [MabThera/Rituxan]
First line chemotherapy
Locations
7
Hungary
National Institute of Oncology, A Dept of Internal Medicine
Budapest, Hungary
University of Debrecen Medical and Health Science Center, Institute of Internal Medicine, Hematology
Debrecen, Hungary
Petz Aladar Megyei Korhaz; Hematologia
Győr, Hungary
Kaposi Mor Teaching Hospital, Dept of Internal Medicine/Hematology
Kaposvár, Hungary
Miskolci Semmelweis Korhaz; Ii Belgyogyaszat
Miskolc, Hungary
University of Szeged, II Dept of Internal Medicine
Szeged, Hungary
Start Date
June 27, 2007
Primary Completion Date
May 25, 2011
Completion Date
May 25, 2011
Last Updated
August 15, 2017
NCT05529069
NCT06263491
NCT05006716
NCT06026319
NCT03523975
NCT01804686
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions